Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04900792 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma
A Phase 1 study of Glioblastoma and Glioblastoma Multiforme, sponsored by Bryan Allen.
- Active
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT04900792 is a Phase 1 study of Glioblastoma and Glioblastoma Multiforme that is active but no longer recruiting, run by Bryan Allen. The registered enrollment target is 17 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04900792, a Phase 1 study of Glioblastoma and Glioblastoma Multiforme, is active but no longer recruiting, sponsored by Bryan Allen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial evaluates adding ferumoxytol and pharamcologic ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive ferumoxytol and pharmacologic ascorbate in addition to the standard treatment.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Ferumoxytol injection
- DRUG Pharmacological ascorbate
- RADIATION External beam radiation therapy
Study Locations (1)
Iowa
- Department of Radiation Oncology at University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04900792
The ClinicalTrials.gov registry entry for NCT04900792 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (84% lower). The listed sponsor is Bryan Allen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which Temozolomide is the first listed.
NCT04900792 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT04900792 about?
NCT04900792 is a clinical study titled "A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma". This clinical trial evaluates adding ferumoxytol and pharamcologic ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive ferumoxytol and pharmacologic ascorbate in addition to the standard treatment.
What is the current status of trial NCT04900792?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2023-02-28. Estimated completion is 2026-12-31.
What conditions does trial NCT04900792 study?
This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme.
What interventions are being tested in trial NCT04900792?
The interventions under investigation include: Temozolomide (DRUG), Ferumoxytol injection (DRUG), Pharmacological ascorbate (DRUG), External beam radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT04900792?
This trial is sponsored by Bryan Allen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04900792 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.